An initial U.S. clinical trial of SYN-2510/IMM2510 as a monotherapy or in combination with chemotherapy as a first-line in patients with non-small cell lung cancer
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs IMM-2510 (Primary) ; Antineoplastics
- Indications Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to Instil Bio media release, the company announced that the trial is planned to initiate in 2H of 2025, assuming the necessary regulatory approvals are obtained.